Innovent’s IBI363 gains NMPA breakthrough therapy designation, boosting regulatory momentum
Innovent’s IBI363 secures NMPA breakthrough therapy designation for melanoma. Discover its clinical potential, investment outlook, and global impact. Read More
Bristol Myers Squibb’s Opdualag fails to meet primary endpoint in Phase 3 trial
Bristol Myers Squibb has announced that its Phase 3 RELATIVITY-098 clinical trial, designed to evaluate Opdualag (nivolumab and relatlimab-rmbw) for adjuvant melanoma treatment, failed to ... Read More
SciBase expands US reach, advancing early melanoma detection with AI-powered technology
SciBase Holding AB (STO: SCIB), a leader in AI-driven dermatology solutions, has taken a significant step forward in its US expansion strategy by onboarding multiple ... Read More
The rising impact of Melanoma: Understanding the risks, causes, and advances in treatment
Melanoma, a severe form of skin cancer, originates in melanocytes, the pigment-producing cells responsible for skin color. Known for its aggressive nature, melanoma can metastasise ... Read More
Achilles Therapeutics shares skyrocket 32% after massive cost cuts—Is this the turnaround it needs?
Achilles Therapeutics PLC saw its American Depositary Receipts (ADRs) soar by an impressive 32%, reflecting renewed investor optimism following the company’s recent announcement of stringent ... Read More
FDA approves Iovance’s AMTAGVI: A breakthrough in melanoma treatment
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a trailblazer in the field of biotechnology focused on developing novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies, has made ... Read More
Moderna, Merck announce promising results for mRNA-4157 and Keytruda in melanoma
Moderna, Inc. (NASDAQ: MRNA) and Merck (NYSE: MRK), also known as MSD outside the United States and Canada, today revealed follow-up data from their collaborative ... Read More
Moderna, Merck get FDA breakthrough status for mRNA-4157/V940, KEYTRUDA combo in melanoma
Moderna and Merck announced that the investigational personalized mRNA cancer vaccine mRNA-4157/V940 in combination with the latter’s lung cancer drug KEYTRUDA (pembrolizumab) has been given ... Read More
ImmVira wraps up first dosing for MVR-T3011 in US and China
ImmVira said that it has wrapped up the first dosing of its oncolytic virus product - MVR-T3011 intratumoral injection in phase 2 clinical trials both ... Read More
OncoSec Medical begins phase 2 trial for TAVO and OPDIVO combination in melanoma treatment
OncoSec Medical, a US-based biotechnology company, has officially dosed the first patient in its phase 2 clinical trial, OMS-104, aimed at evaluating the combination of ... Read More